Effient
Links shared publicly online about this topic
EFFIENT - New Product Releases - MPR
empr.com — “To reduce risk of thrombotic cardiovascular events in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI); patients with ST-elevation MI (STEMI) when managed with either primary or delayed PCI).” View full resource at empr.com
Most Recently Shared on August 14, 2009 at 1:44 pm By:
Physician Assistants Health News Feed
New drug Effient: http://www.empr.com/effient/drugproduct/75/ reduce risk of thrombotic CV events in patients with acute coronary syndrome
Effient Sanctioned for Angioplasty Patients - Drugs.com MedNews
drugs.com — “The U.S. Food and Drug Administration has approved the Eli Lilly blood-thinner Effient (prasugrel) to prevent clots in people who have an artery-clearing proced” View full resource at drugs.com
Most Recently Shared on July 11, 2009 at 7:49 pm By:
FDA Approves Effient for Angioplasty Patients - http://bit.ly/VcQ76
Blood thinner Effient gets FDA approval with warning - USATODAY.com
usatoday.com — “The U.S. Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.” View full resource at usatoday.com
Most Recently Shared on July 11, 2009 at 12:46 pm By:
Plavix, world's 2nd-best-selling #drug, has new competitor that comes with boxed warning about bleeding. http://tr.im/rSlf #FDA #health
Healthy growth for Lilly but Effient doubts raised | InPharm
inpharm.com — “Healthy growth for Lilly but Effient doubts raised | InPharm” View full resource at inpharm.com
Most Recently Shared on February 1, 2010 at 12:15 pm By:
Pharmafocus Health News and Pharma
Healthy growth for Lilly but Effient doubts raised. Full year revenues rise 7% on the back of Zyprexa sales. http://ow.ly/12ven
FDA Approves Effient, A Challenger to Plavix - WSJ.com
online.wsj.com — “The FDA approved the blood-thinning drug Effient in a long-awaited victory for its developers, Eli Lilly and Daiichi.” View full resource at online.wsj.com
Most Recently Shared on July 11, 2009 at 12:52 am By:
FDA Approves Effient, a Plavix Rival http://tinyurl.com/lumw62
Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation
news-medical.net — “A study evaluating the level of platelet aggregation achieved after switching from Plavix (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient(prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.” View full resource at news-medical.net
Most Recently Shared on September 14, 2010 at 7:28 am By:
Stroke News: Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation: A study evaluating ... http://twurl.nl/jqo0zn
Daiichi Sankyo And Lilly Receive U.S. FDA Approval For Effient(TM)
medicalnewstoday.com — “Daiichi sankyo, inc. and eli lilly and company (nyse: lly) announced that the u.s. food and drug administration (fda) approved effient(tm) (prasugrel) tablets for the reduction of thrombotic card” View full resource at medicalnewstoday.com
Most Recently Shared on July 11, 2009 at 11:17 am By:
MedicalNewsToday: Daiichi Sankyo And Lilly Receive U.S. FDA Approval For: http://tinyurl.com/lzkkyz Full http://tinyurl.com/l3c87u
Approval of Effient, a Plavix Rival, Boosts Japanese Drug Maker - Health Blog - WSJ
blogs.wsj.com — “The blood thinner marks the first time in a while that a Japanese-originated drug has a shot at becoming a blockbuster.” View full resource at blogs.wsj.com
Most Recently Shared on July 11, 2009 at 12:14 am By:
Approval of Effient, a Plavix Rival, Boosts Japanese Drug Maker http://bit.ly/LTorJ
The IN VIVO Blog: Effient and Onglyza Start Slow—And That May Not Be A Bad Thing
invivoblog.blogspot.com — “The IN VIVO Blog: Effient and Onglyza Start Slow—And That May Not Be A Bad Thing” View full resource at invivoblog.blogspot.com
Most Recently Shared on October 26, 2009 at 2:37 pm By:
Chris Morrison Health Communicator
read this from @RPMReportMike on why slow starts for Effient and Onglyza may not be such bad news. http://bit.ly/4wWjMc
ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI
news-medical.net — “Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.” View full resource at news-medical.net
Most Recently Shared on March 30, 2011 at 10:05 am By:
Stroke News: ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI: Ora... http://twurl.nl/0nduly
The IN VIVO Blog: Plavix Label Change: Good For Effient Now, Bad For Brands in the Long Run?
invivoblog.blogspot.com — “The IN VIVO Blog: Plavix Label Change: Good For Effient Now, Bad For Brands in the Long Run?” View full resource at invivoblog.blogspot.com
Most Recently Shared on November 19, 2009 at 7:42 am By:
Chris Morrison Health Communicator
@RPMReportMike has some interesting things to say about what FDA's Plavix warning means 4 all brands in the long run http://bit.ly/4wMk3H
New Updates To AHA/ACC/SCAI Clinical Guidelines Recommend Treatment With Effient(R) For Patients With Acute Coronary Syndromes Managed With PCI
medicalnewstoday.com — “Effient(r) (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (pci) ” View full resource at medicalnewstoday.com
Most Recently Shared on November 28, 2009 at 11:15 am By:
MNT Cardiovascular Health News
New Updates To AHA/ACC/SCAI Clinical Guidelines Recommend Treatment With Effient(R) For Patients With Acute Cor.. http://bit.ly/8fKvQb
Mortality Data Presented For Patients Treated With Effient® Who Underwent Isolated Coronary Artery Bypass Surgery
medicalnewstoday.com — “New results from an observational substudy from TRITON TIMI 38 presented at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Effient® (” View full resource at medicalnewstoday.com
Most Recently Shared on November 17, 2010 at 8:05 pm By:
MNT Clinical Trials Health News
Mortality Data Presented For Patients Treated With Effient® Who Underwent Isolated Coronary Artery Bypass Surgery http://mnt.to/3MJz
Phase II Study Showed Switching ACS-PCI Patients To Effient®/aspirin From Plavix®/aspirin Regimen Reduced Maximum Platelet Aggregation
medicalnewstoday.com — “A study evaluating the level of platelet aggregation achieved after switching from Plavix® (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient® (prasugrel) 10 mg onc” View full resource at medicalnewstoday.com
Most Recently Shared on September 14, 2010 at 1:38 pm By:
MNT Clinical Trials Health News
Phase II Study Showed Switching ACS-PCI Patients To Effient®/aspirin From Plavix®/aspirin Regimen Reduced Maxi... http://mnt.to/3JHJ
Comments of using Omega 3, Ginkgo Biloba, Carisoprodol And Aspirin, Effient, Isosorbide Mononitrate, Folic Acid, Colestipol Hydrochloride (study 6137656) - eHealthMe.com
ehealthme.com — “indigestion and constipation all the time” View full resource at ehealthme.com
Most Recently Shared on March 21, 2012 at 7:48 pm By:
indigestion and constipation all the time http://t.co/V38lLb8l
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Physician Assistants
- Physician Assistants (P.A.) are licensed health professionals who practice medicine with the supervision of a physician
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
RitaRubin
I write about drug safety, the FDA, women's health, to name a few medical topics, for USA TODAY.
Advertisement
